Clinical Trial: Efficacy, Safety, PK, PD and HRQoL of 2 Dose Levels and Regimens of ADX-324 in Preventing HAE Attacks Compared With Placebo in Participants With Type 1 and Type II HAE

U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06960213) titled 'Efficacy, Safety, PK, PD and HRQoL of 2 Dose Levels and Regimens of ADX-324 in Preventing HAE Attacks Compared With Placebo in Participants With Type 1 and Type II HAE' on April 07.

Brief Summary: This Phase 3 study will evaluate the efficacy of 2 dose levels and regimens of ADX-324 in preventing HAE attacks compared with placebo in participants with Type I and Type II HAE. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life (HRQoL) measures.

Study Start Date: May 31

Study Type: INTERVENTIONAL

Condition: Hereditary Angioedema

Intervention: DRUG: ADX-324

siRNA dup...